Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear. METHODS: We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of the International Myeloma Working Group for the diagnosis of smoldering multiple myeloma between 1970 and 1995. Bone marrow aspirate and biopsy specimens were studied, and patients were followed throughout the course of disease. RESULTS: During the 26-year period, 276 patients fulfilled the criteria for smoldering multiple myeloma. During 2131 cumulative person-years of follow-up, symptomatic multiple myeloma or amyloidosis developed in 163 persons (59%). The overall risk of progression was 10% per year for the first 5 years, approximately 3% per year for the next 5 years, and 1% per year for the last 10 years; the cumulative probability of progression was 73% at 15 years. At diagnosis, significant risk factors for progression included the serum level and type of monoclonal protein, the presence of urinary light chain, the extent and pattern of bone marrow involvement, and the reduction in uninvolved immunoglobulins. The proportion of plasma cells in the bone marrow and the serum monoclonal protein level were combined to create a risk-stratification model with three distinct prognostic groups. CONCLUSIONS: The risk of progression from smoldering multiple myeloma to symptomatic disease is related to the proportion of bone marrow plasma cells and the serum monoclonal protein level at diagnosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with SMM have a risk of progression of approximately 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% per year thereafter.19”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [19]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationManual of Clinical Laboratory Immunology
Rose, N. R., Hamilton, R. G., & Detrick, B. (1992) · Cited by 1,250
Cited by
Items 801–900 of 932
Balanco, L. P. (2016) · Estudo Geral (Universidad de Coimbra)
Genome instability in multiple myeloma-associated DIS3 exonuclease domain mutants
Milbury, K. L. (2018) · cIRcle (University of British Columbia) · doi:10.14288/1.0375808
“Patients eventually progression to “smoldering phase”, a further (often asymptomatic) stage where monoclonal protein in the serum and risk of progression rise substantially (Kyle et al., 2007).”
Role of Standard Magnetic Resonance Imaging
Salizzoni, E., Conficoni, A., & Coe, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-19019-4_4
Touzeau, C., & Moreau, P. (2019) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(19)42057-7
Early Intervention in Smoldering Myeloma
Kumar, S. K. (2019) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2019.15.1.14
Therapeutic Advances in the Management of Smoldering Myeloma
Khan, R., Zahid, U., Kollu, V. S., Jahan, N., McBride, A., Tricot, G. J. K., & Anwer, F. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001034
Plasma cell myeloma and related monoclonal gammopathies
Rajkumar, S. V., & Kyle, R. A. (2020) · doi:10.1093/med/9780198746690.003.0527
Self-citation[A 55-year-old male with anemia and monoclonal gammopathy].
Qiu, Y., Jiang, X., Luo, Y., Li, J., Zhou, D., & Cao, X. (2019) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2019.09.017
Hämatologische und onkologische Erkrankungen
Schrezenmeier, H., & Hiller, E. (2011) · Elsevier eBooks · doi:10.1016/b978-3-437-22702-8.50012-1
Diagnosis and Treatment of Multiple Myeloma for Spinal Surgeons
Kinoshita, R., & Yokose, N. (2020) · Spinal Surgery · doi:10.2531/spinalsurg.34.134
Fend, F. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316535042.016
Hämatologische und onkologische Erkrankungen
Gstatter, S., & Berthold, H. K. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-45381-6.00039-6
Clinical and Immunological Aspects of Pneumococcal Vaccination in Patients with Multiple Myeloma
Стома, И. О. (2021) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2020-19-6-79-85
Buitrago-Toro, K., Perdomo, L. C. Á., Leiva, L. M., Chavarro, A. F. M., Castañeda, C. P., & Jiménez-Salazar, S. (2020) · Galicia Clínica · doi:10.22546/58/1930
Genetic Alterations In Turkish Patients With Multiple Myeloma: A Single Center Experience
Bakırtaş, M., Bahsi, T., Yiğenoğlu, T. N., Erdem, H. B., Çakar, M. K., Dal, M. S., & Altuntaş, F. (2020) · Acta Oncologica Turcica · doi:10.5505/aot.2020.02439
Smoldering Myeloma Treatment: Who, What, and When
Saldarriaga, M. M., & Rossi, A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000528
Gupta, V. A., Joseph, N. S., & Jaye, D. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-73227-1_17
Hammad, Z. A. A., Hernández, E., & Tate, S. (2021) · Journal of Family Medicine · doi:10.26420/jfammed.2021.1261
“SMM carries a significantly higher risk of progression to MM with 10% chance of malignancy annually for the first 5 years (51% rate of progression to MM or AL) [17].”
BackgroundProgression and Free Progression Survival Indices in Patients with Multiple Myeloma
Abdullah, S. A., Tameemi, W. F. A., & Al-Shamma, G. A. A. (2021) · Medico-Legal Update · doi:10.37506/mlu.v21i2.2826
“However, many parameters were suggested for these purposes, some concern demographic characteristics as age, residence, gender, race, or obesity (8-10), others are related to diagnostic results as radiology or laboratory findings as Hb, plasma cells, renal insufficiency, hypercalcemia, β2microglobulin, free light chai…”
BackgroundMultiple Myeloma Surveillance Counterpoint: Australia
Khoo, L., & Joshua, D. (2012) · Humana Press eBooks · doi:10.1007/978-1-60327-969-7_100
Progression of Smoldering (Asymptomatic) Multiple Myeloma
Dispenzieri, A. A., & Larson, D. R. (2013)
Self-citationGouill, S. L., & Touzeau, C. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717954851.793463984
Leleu, X. P. (2009) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1166264.627201
Monoclonal Gammopathies of Undetermined Significance and Smoldering Multiple Myeloma
Lust, J. A., Jelinek, D. F., & Donovan, K. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8520-9_7
Self-citationDifferential diagnosis – chromosomal/molecular changes
Gorczyca, W., & Emmons, F. N. (2008) · CRC Press eBooks · doi:10.3109/9781439806487-16
Current Awareness in Hematological Oncology
(2008) · Hematological Oncology · doi:10.1002/hon.830
Singla, A., & Kumar, S. K. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5260-7_8
Bain, B. J., Clark, M. D. M., & DM, B. S. W. (2019) · Wiley eBooks · doi:10.1002/9781119398929.ch7
Surgical treatment of a frontal bone lesion in a patient with multiple myeloma
Skalický, P., & Bradáč, O. (2022) · Onkologie · doi:10.36290/xon.2022.008
Targeting α4 Integrin Containing Complexes in Multiple Myeloma Using Peptidomimetics
Emmons, M. F. (2012) · Digital Commons - University of South Florida (University of South Florida)
Spaan, I. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1172
Schulz, C. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-21215-4.00014-7
Álvarez, I. H., Gómez, Y. C., & Mera, J. G. Z. (2018) · Revista Mexicana de Urología · doi:10.48193/revistamexicanadeurologa.v78i4.86
Mateos, M., & Miguel, J. F. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_26 · Cited by 1
Mitsiades, C. S., Anderson, K. C., & Richardson, P. G. G. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199358274.003.0016
Study identifies risk factors for progression of smoldering multiple myeloma
(2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0918
Vascular and Stromal Contributions to Tumor Bone-Homing: Focus on Multiple Myeloma
Federico, C., Sacco, A., Belotti, A., Ribolla, R., Cancelli, V., Giacomini, A., Ronca, R., Chiarini, M., Imberti, L., Marini, M., et al. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11240-1
Tantravahi, S. K., & Kovacsovics, T. J. (2015) · Springer eBooks · doi:10.1007/978-1-4614-5662-9_9
Sun, N. C. J., Wang, J., Zhao, X. S., & Glassy, E. F. (2015) · Cambridge University Press eBooks · doi:10.1017/9781139137201.013
E28 Literaturhinweise und Internetadressen
(2015) · Elsevier eBooks · doi:10.1016/b978-3-437-21213-0.16001-2
Mina, R., & Palumbo, A. P. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2837-3_12
Dmoszyńska, A., Walter‐Croneck, A., Usnarska‐Zubkiewicz, L., Stella-Holowiecka, B. M., Walewski, J. A., Charliński, G., Wiktor-Jędrzejczak, W., Wiater, E., Lech‐Marańda, E., Dytfeld, D., et al. (2015) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2015.04.004
(2012) · Elsevier eBooks · doi:10.1016/b978-0-323-08373-7.00022-4
Schulz, C. (2017) · Elsevier eBooks · doi:10.1016/b978-3-437-21214-7.00014-6
Yared, M. A., & Lorsbach, R. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-42370-8_1
Clinical Application and Limitations of Myeloma Response Assessment and Diagnosis System (MY-RADS)
Kim, D. K., Park, S., & Jung, J. (2023) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2022.0154
“SMM의 경우에는 MDEs인 5 mm 이상 국소병변의 발견에 노력을 기울여야 한다(Fig.”
InfluentialMonoklonale Gammopathie unklarer Signifikanz und Smoldering Multiples Myelom
Schenk, A., & Besemer, B. (2023) · TumorDiagnostik & Therapie · doi:10.1055/a-1981-0072
Maura, F., Landgren, O., & Morgan, G. J. (2023) · doi:10.1158/1078-0432.c.6530273
Termini, R., Žihala, D., Terpos, E., Pérez-Montaña, A., Jelínek, T., Raab, M. S., Weinhold, N., Mai, E. K., Grab, A. L., Corre, J., et al. (2023) · doi:10.1158/1078-0432.c.6532880
Maura, F., Landgren, O., & Morgan, G. J. (2023) · doi:10.1158/1078-0432.c.6530273.v1
Li, S., Suehs, B. T., Fu, A., Sangaré, L. R., Kim, C., Gastañaga, V. M., Liu, J., Yan, H., Xu, Y., & Mikhael, J. R. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.04.009
Aquil, M., Giles, H. V., Buka, R. J., & Bano, F. (2023) · BMJ Case Reports · doi:10.1136/bcr-2022-252917
Single-cell characterization of tumor evolution from precursor diseases
Feng, J., Zeng, Y., & Li, S. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.012
EXABS-121-MM MGUS/SMM: Incidence, Evaluation and Follow-up
Schmidt, T. M., & Callander, N. S. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(23)00292-6
Early intervention for high risk smoldering multiple myeloma (SMM)
Chen, P., Jhou, H., Ho, C., Huang, H.-L., & Lee, C. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015494
The Age of Immune-therapy in Multiple Myeloma with a Collective Goal for a Cure
Larios, J. M., & Terebelo, H. R. (2023) · Medical Research Archives · doi:10.18103/mra.v11i10.4607
Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma
Boquoi, A. (2023) · Journal of Blood Disorders · doi:10.26420/jblooddisordl.2023.1082
Monoclonal Gammopathy of Ocular Significance – A Case Report
Said, S., Schwotzer, R., Muth, D. R., Fasler, K., Barthelmes, D., Zweifel, S. A., & Blaser, F. (2024) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-2211-9351
“Never-theless, SMM carries a 10% per year risk of progression to symptomatic multiple mye-lomaover5yearsanda 65% cumulative risk 10 years after diagnosis [5].”
BackgroundIntroduction to Multiple Myeloma and Multiple Myeloma Bone Disease
Esteghamat, N., & Abedi, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-52001-3_10
The Difficulty in Defining the True High-Risk Smoldering Myeloma
Weinhold, N., & Rasche, L. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1382
PLASMA CELL NEOPLASMS AND RELATED CONDITIONS
Bain, B. J., David M. Clark MD, M. (., Bridget S. Wilkins DM, P., & Vishakha Sovani MBBS, M. (2024) · Wiley eBooks · doi:10.1002/9781394244843.ch7
Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions
Cicero, K. I., Banerjee, R. K., Kwok, M., Dima, D., Portuguese, A. J., Chen, D. L., Chalian, M., & Cowan, A. J. (2025) · Diagnostics · doi:10.3390/diagnostics15020215
“In contrast, SMM represents a more advanced precursor condition with a greater risk of progression to active MM: a 10% annual risk of progression to malignancy for the first 5 years, followed by a reduced risk of 2–3% per year thereafter [4].”
[Progress in risk stratification and treatment of high-risk smoldering multiple myeloma].
Zhou, J. Q., Hao, M., & An, G. (2024) · PubMed Central · doi:10.3760/cma.j.cn121090-20240416-00144
Szita, V. R. (2025) · Hematológia–Transzfuziológia · doi:10.1556/2068.2025.00202
Risk factors of Asymptomatic (Smoldering) Multiple Myeloma
Machálková, K., & Maisnar, V. (2014) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2014.014
Hirano, D., Iida, H., Iwakoshi, A., Sunohara, A., Suzuki, M., Suzuki, Y., Imahashi, N., Adachi, T., & Nagai, H. (2025) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.25001
“17,18 The criteria for “high-risk SMM” in this report were “serum M-protein level ≥3 g/dL and abnormal plasma cells percentage in bone marrow ≥10%”, which the present case met.”
Immunochemical measurement of urinary free light chains and Bence Jones proteinuria
Michetti, L., Ravasio, R., Marozzi, R., Antelmi, E., Ghirardi, A., & Bolzoni, G. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-0265
Varga, C., Zimmerman, K. D., Foureau, D., Nazli, S. A., Voorhees, P. M., Atrash, S., Paul, B. A., Ferreri, C. J., Olivier, M., & Bhutani, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.008
Costello, C. L., & Fonseca, R. (2022) · doi:10.1182/ashsap8.chapter25
Self-citationTheprungsirikul, P. P., Wang, R., Ahmad, I., Neparidze, N., Ma, X., Chang, S., & Wang, S. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.016
ASH 2024: highlights in multiple myeloma
Udovica, S., & Schreder, M. (2025) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-025-01051-6
“Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by a variable risk of progression to symptomatic MM [1].”
Tao, Y., Yuan, L., Ding, Y., Xie, R., Liu, F., Zhang, Z., Xu, X., & Wang, X. (2025) · Biomedicines · doi:10.3390/biomedicines13092086
“SMM represents an intermediate asymptomatic stage, characterized by a greater clonal plasma cell burden in the bone marrow but without clinical end-organ damage, and carries an annual progression risk of approximately 10% [9].”
Pires, A. M., Barreto, J. P., Caetano, J., Soares, M. J., Geraldes, C., Fernandes, B., Coucelo, M., Chacim, S. P., Coelho, H. G. B., Correia, C., et al. (2025) · Acta Médica Portuguesa · doi:10.20344/amp.22909
Barrale, M., SASSO, M., Cinquanta, L., Sorrentino, M. C., PETRANCOSTA, R., SCEUSA, G., TREVISAN, M. T., Mangraviti, S., Biasioli, B., & Brusca, I. (2025) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.23736/s1825-859x.25.00303-2
Czernilofsky, F., & Raab, M. S. (2025) · Trillium Krebsmedizin · doi:10.47184/tk.2025.05.1
Niu, C. (2025) · International Journal of Clinical and Experimental Pathology · doi:10.62347/olmg7236
Developing antisense therapeutics for multiple myeloma
Kapphahn, A., Truong, N., Khan, M., Ashitey, A., Alfano, D., & Gupta, A. (2025) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2025.102923
Smoldering multiple myeloma in the United States: a population-based analysis
Wang, S., Wang, R., Schoen, M. W., Huber, J. H., Feuer, E. J., Ruhl, J., Neparidze, N., Ma, X., Davidoff, A. J., & Chang, S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017817
Three-Dimensional Organization of Telomeres: An Emerging Prognostic Biomarker in Multiple Myeloma
Shifrin, Y., & Mai, S. (2025) · Cells · doi:10.3390/cells14231890
“However, in around 1% of MGUS patients, the disease progresses to the intermediate stage, SMM, which represents a more advanced but still asymptomatic form of MM [12].”
Erol, V., Avcı, E., Hacıoğlu, S., Güler, N., Çağlıyan, G. A., Koluman, B. Ü., Kendir, İ. C., Elver, Ö., Kara, K., Kaya, E., et al. (2025) · Cureus · doi:10.7759/cureus.98204
Uehara, A., Narita, K., Fujii, F., Sakuma, H., Oura, M., Toho, M., Ikeda, D., Tabata, R., Takeuchi, M., & Matsue, K. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04117-7
Cade, J. F. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511835278.014
Hk, P., Zhan, F., & Shaughnessy, J. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmc072069
Jean-Baptiste, M., Gries, K. S., Lenderking, W. R., & Fastenau, J. M. (2021) · Figshare · doi:10.6084/m9.figshare.14433299
Emery, A., Moore, S. E., Crowe, J., Murray, J., Peacock, O. J., Thompson, D., Betts, F., Rapps, S., Ross, L. S., Rothschild-Rodriguez, D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26676986
Exploring the role of APOBEC3B cytosine deaminase in high-risk multiple myeloma
Panahi, A. (2025) · cIRcle (University of British Columbia) · doi:10.14288/1.0448439
Gonsalves, W. I., Jang, J. S., Jessen, E., Hitosugi, T., Evans, L. A., Jevremović, D., Pettersson, X.-M., Bush, A. G., Gransee, J., Anderson, E. I., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13467787
Giraldos Jimenez, D., Anel Bernal, L. A., & Naval Iraberri, J. J. (2023) · Zaguan (University of Zaragoza Repository)
Mechanismy rezistence mnohočetného myelomu - buněčný model
Rubínová, K. (2024) · Digital library - University of Pardubice (University of Pardubice)
Mieloma múltiple : canvis en el maneig clínic associats a la incorporació de nous fàrmacs
Gassiot-Riu, S., & de Medicina, U. A. D. B. D. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Rögnvaldsson, S. (2023) · Opin vísindi (Opin vísindi) · Cited by 2
Bergantim, R. F. C. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/2z1w-9c87
Han, M. H., & Jeong, T. (2025) · Laboratory Medicine Online · doi:10.47429/lmo.2026.16.1.32
Corrêa, B. D. S. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Navigating the evolving management of smoldering multiple myeloma
Hammami, M. B., Canevarolo, R. R., Silva, A. S., Alsina, M., Kumar, N. B., Baz, R., & Shain, K. H. (2026) · HemaSphere · doi:10.1002/hem3.70275
“12 17 They had previously demonstrated that aberrant plasma cells (aPCs) are identified by immunophenotypic analysis with the absence of CD19 and/or CD45, decreased expression of CD38, and overexpression of CD56.”
Temporal trends in progression risk in smoldering myeloma: a systematic review
Ludwig, H., Kastritis, E., Bernhard, S., van de Donk, N. W. C. J., Boccadoro, M., Terpos, E., Musto, P., Sonneveld, P., & Mohyuddin, G. R. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103750
“15 To determine whether the risk of progression decreases with longer follow-up, as initially demonstrated by Kyle et al., 2 we conducted a landmark analysis at five years.”
Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022
Wang, R., Davidoff, A. J., Schoen, M. W., Huber, J. H., Feuer, E. J., Ruhl, J., Neparidze, N., Ma, X., Chang, S.-H., & Wang, S.-Y. (2026) · American Journal of Hematology · doi:10.1002/ajh.70202
Metadata
- Authors
- Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., Melton, L. J., & Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-21
- Volume
- 356
- Issue
- 25
- Pages
- 2582-2590
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1974983065
- Cited by
- 921
- References
- 25
- Citations by year
- 2026: 34 · 2025: 57 · 2024: 62 · 2023: 48 · 2022: 56 · 2021: 69 · 2020: 70 · 2019: 45 · 2018: 49 · 2017: 37 · 2016: 55 · 2015: 46 · 2014: 50 · 2013: 56 · 2012: 42
- FWCI
- 21.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 107 476, CA6 2242, R01CA107476, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- smoldering multiple myeloma, asymptomatic multiple myeloma, amyloidosis, prognostic factors, risk stratification, clinical course
- MeSH terms
- Adult, Aged, Aged, 80 and over, Amyloidosis, Antibodies, Monoclonal, Biopsy, Bone Marrow Cells, Bone Marrow Examination, Female, Humans, Male, Middle Aged, Multiple Myeloma, Plasma Cells, Prognosis, Risk Factors, Cohort Studies, Disease Progression, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.